Current radiotherapy techniques in NSCLC: challenges and potential solutions

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2017, National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/csr/1975_2017/
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Lung Cancer Survival Rates - American Cancer Society, 2019. Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html
   Google Scholar
• Bradley JD, Hu C, Komaki RR, et al., Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage iii non–small-cell lung cancer. J Clin Oncol. 38(7): 706–714. 2020.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28(suppl_4):iv1–21.
   PubMed Web of Science ®Google Scholar
• Aupérin A, Le Péchoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2013;106(3):276–282.
   Google Scholar
• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076.
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:295–301.
   PubMed Web of Science ®Google Scholar
• Louie AV, Palma DA, Dahele M, et al. Management of early stage non small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Rdaiother Oncol. 2015;114:138–147.
   PubMed Web of Science ®Google Scholar
• Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? Br J Radiol. 2012;85:e770–e781.
   PubMed Web of Science ®Google Scholar
• Wang JZ, Li XA. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys. 2005;61(1):220–227.
   PubMed Web of Science ®Google Scholar
• Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the nordic countries. Acta Oncol. 2006;45:787–795.
   PubMed Web of Science ®Google Scholar
• Shibamoto Y, Miyakawa A, Otsuka S, et al. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res. 2016;57(Suppl 1):i76–i82.
   PubMedGoogle Scholar
• Park HJ, Griffin RJ, Hui S, et al. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–327.
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–1159.
   PubMed Web of Science ®Google Scholar
• Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage i non–small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–5159.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Andratschke N, Dieckmann K, et al., ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017; 124(1): 11–17.
   PubMed Web of Science ®Google Scholar
• Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, 2020. NCCN clinical practice guidelines in oncology: lung cancer,version 3.2020. (Cited 2020 February 17). Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Stokes WA, Rusthovn CG. Surgery vs. SBRT in retrospective analyses: confounding by operability is the elephant in the room. J Thorac Dis. 2018;10(Suppl 17):S2007–S2010.
   PubMedGoogle Scholar
• Chang JY, Senan S, Paul MA, et al., Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 16(6): 630–637. 2015.
   PubMed Web of Science ®Google Scholar
• Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24(6):1543–1548.
   PubMed Web of Science ®Google Scholar
• Hamaji M, Chen F, Matsuo Y, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015;99(4):1122–1129.
   PubMed Web of Science ®Google Scholar
• Li M, Yang X, Chen Y. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:2885–2892.
   PubMed Web of Science ®Google Scholar
• Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623–1631.
   PubMed Web of Science ®Google Scholar
• Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation. Chest. 2003;124(5):1946–1955.
   PubMedGoogle Scholar
• McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–1015.
   PubMed Web of Science ®Google Scholar
• Daly ME, Perks JR, Chen AM. Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol. 2013;8(2):202–207.
   PubMed Web of Science ®Google Scholar
• Singh AK, Gomez-Suescun A, Stephans KL. One versus three fractions of stereotactic body radiation therapy for peripheral stage i to ii non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys. 2019;105(4):752–759.
   PubMed Web of Science ®Google Scholar
• Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–4839.
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase ii study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682.
   PubMed Web of Science ®Google Scholar
• Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Practical Radiation Oncology. 2016;6(2):e27–e33.
   PubMed Web of Science ®Google Scholar
• Lindberg K, Bergstrom P, Brustugun OT, et al. OA24.05 the nordic HILUS-trial - first report of a phase ii trial of SBRT of centrally located lung tumors. J Thorac Oncol. 2017;12(1):S340.
   Web of Science ®Google Scholar
• Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer. 2015;89(1):50–56.
   PubMed Web of Science ®Google Scholar
• Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non–small-cell lung cancer: NRG oncology/RTOG 0813 Trial. Clin Oncol. 2019;37(15):1316–1325.
   Web of Science ®Google Scholar
• Singh AK, Gomez-Suescun JA, Stephans KL, et al. One versus three fractions of stereotactic body radiation therapy for peripheral stage i to ii non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys. 2019;105(4):752–759.
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Hu C, Singh AK, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage i peripheral non-small cell lung cancer: nrg oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2008;88(4):757–764.
   Google Scholar
• Selvaraj J, Lebesque J, Hope A, et al. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: the impact of a local dose–effect relationship for lung perfusion loss. Radiother Oncol. 2019;132:142–147.
   PubMed Web of Science ®Google Scholar
• Choi JI. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes. Transl Lung Cancer Res. 2018;8(1):32–47.
   Web of Science ®Google Scholar
• Senthi S, Haasbeek CJA, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106(3):276–282.
   PubMed Web of Science ®Google Scholar
• Bezjak A, Paulus R, Gaspar LE, et al. Efficacy and toxicity analysis of NRG oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2016;96(2):S8.
   Google Scholar
• RWM U, FJ L, JP C, et al. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:1283–1290.
   PubMed Web of Science ®Google Scholar
• Keall PJ, Mageras GS, Balter JM, et al. The management of respiratory motion in radiation oncology report of AAPM task group 76. Med Phys. 2006;33:3874.
   PubMed Web of Science ®Google Scholar
• Josipovic M, Persson GF, Logadottir Á, et al. Translational and rotational intra- and inter-fractional errors in patient and target position during a short course of frameless stereotactic body radiotherapy. Acta Oncologica. 2012;85(5):610–617.
   Google Scholar
• Borst GR, Sonke -J-J, Betgen A, et al. Kilo-voltage cone-beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device. Int J Radiat Oncol Biol Phys. 2016;107(2):555–561.
   Google Scholar
• Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–1431.
   PubMed Web of Science ®Google Scholar
• Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51(3):666–670.
   PubMed Web of Science ®Google Scholar
• Shirato H, Shimizu S, Kunieda T, et al. Physical aspects of a real-time tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(4):1187–1195.
   PubMed Web of Science ®Google Scholar
• Onishi H, Kuriyama K, Komiyama T, et al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer. 2004;45(1):45–55.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Alongi F, Castiglioni S, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;6(1):113.
   PubMedGoogle Scholar
• Snider JW, Oermann EK, Chen V, et al. CyberKnife with tumor tracking: an effective treatment for high-risk surgical patients with single peripheral lung metastases. Front Oncol. 2012;2:1–5.
   Google Scholar
• Jung J, Song SY, Yoon SM, et al. Verification of accuracy of cyberknife tumor-tracking radiation therapy using patient-specific lung phantoms. Int J Radiat Oncol Biol Phys. 2015;92(4):745–753.
   PubMed Web of Science ®Google Scholar
• Baumann P, Nyman J, Hoyer M, et al. Outcome in a PROSPECTIVE PHASE II TRIAL OF MEDICALLY INOPERABLE STAGE I NON–SMALL-CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIotherapy. Clin Oncol. 2009;27(20):3290–3296.
   Web of Science ®Google Scholar
• Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage i non–small-cell lung cancer: five-year mature results. J Thorac Oncol. 2017;97(6):960–964.
   Google Scholar
• Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2019;9(5):989–996.
   Google Scholar
• Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: results of a phase 2 clinical trial. Cancer. 2017;123(16):3031–3039.
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage i non–small cell lung cancer. JAMA Oncology. 2007;4(9):1287.
   Google Scholar
• Chen VW, Ruiz BA, Hsieh M-C, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120:3781–3792.
   PubMed Web of Science ®Google Scholar
• Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 2020;15(2):288-293.
   PubMedGoogle Scholar
• Dağoğlu N, Karaman S, Arifoğlu A, et al. Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation. Balkan Medical Journal. 2015;31(4):278–285.
   Web of Science ®Google Scholar
• Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group. Cancer. 1980;45:2744–2753.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–199.
   PubMed Web of Science ®Google Scholar
• Brown S, Banfill K, Aznar MC, et al. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol. 2019;92(1104):20190524.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Hodgson L, Herndon JE, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thoracic Oncol. 2012;3(9):1117–1125.
   Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Chang JY, Dong L, Liu H, et al. Image–guided radiation therapy for non–small cell lung cancer. J Thorac Oncol. 2004;14(2):177–186.
   Google Scholar
• Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2017;6(1):1–5.
   Google Scholar
• Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys. 2006;64:435–448.
   PubMed Web of Science ®Google Scholar
• Slotman BJ, Lagerwaard FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncol. 2006;45:966–972.
   PubMed Web of Science ®Google Scholar
• Liu HH, Balter P, Tutt T, et al. Assessing respiration induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:531–540.
   PubMed Web of Science ®Google Scholar
• Nestle U, Schimek-Jasch T, Kremp S, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21:581–592.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Faivre-Finn C, Moeller D, et al. European organization for research and treatment of cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124:1–10.
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Faivre-Finn C, Nestle U, et al. European organisation for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28:5301–5310.
   PubMed Web of Science ®Google Scholar
• Sher DJ, Koshy M, Liptay MJ, et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III nonsmall cell lung cancer in the national cancer data base. Cancer. 2014;120:2060–2068.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou Z, Liang J, et al. Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy. Oncologist. 2016;21:1530–1537.
   PubMed Web of Science ®Google Scholar
• Schwarz M, Van der Geer J, Van Herk M, et al. Impact of geometrical uncertainties on 3D CRT and IMRT dose distributions for lung cancer treatment. Int J Radiat Oncol Biol Phys. 2006;65:1260–1269.
   PubMed Web of Science ®Google Scholar
• Liao ZX, Komaki RR, Thames HD Jr., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced nonsmall-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:775–781.
   PubMed Web of Science ®Google Scholar
• Chang JY. Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer. Semin Radiat Oncol. 2015;25:110–116.v.
   PubMed Web of Science ®Google Scholar
• Appel S, Bar J, Ben-Nun A, et al. Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes. Br J Radiol. 2019;92:20180960.
   PubMed Web of Science ®Google Scholar
• Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT),3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–890.
   PubMed Web of Science ®Google Scholar
• Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensitymodulated radiotherapy for advanced-stage nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58:1258–1267, Erratum: Int J Radiat Oncol Biol Phys 59:921, 2004
   PubMed Web of Science ®Google Scholar
• Chen AB, Li L, Cronin A, et al. Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol. 2014;9:1788–1795.
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Comparison of 3-D conformal and intensity modulated radiation therapy outcomes for locally advanced non-small cell lung cancer in NRG Oncology/RTOG 0617. Int J Radiat Oncol Biol Phys. 2015;93:S1–S2.
   PubMedGoogle Scholar
• Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stagenon-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102.
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.
   PubMed Web of Science ®Google Scholar
• Dess RT, Sun Y, Muenz DG, et al. Cardiac Dose in Locally Advanced Lung Cancer: results From a Statewide Consortium. Pract Radiat Oncol. 2020;10:e27–e36.
   PubMed Web of Science ®Google Scholar
• Giaj-Levra N, Sciascia S, Fiorentino A, et al. Radiotherapy in patients with connective tissue diseases. Lancet Oncol. 2016;17:e109–e117.
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer. 2016;17(4):29.
   Google Scholar
• Tubin S, Ashdown M, Jeremic B. Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment. Radiat Oncol. 2019;14:220.
   PubMed Web of Science ®Google Scholar
• Tubin S, Khan MK, Salerno G, et al. Mono-institutional phase 2 study of innovative stereotactic body radiotherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment. Radiat Oncol. 2019;14:212.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Bhattacharya IS. Protons and more: state of the art in radiotherapy. Clin Med (Lond). 2014;14(Suppl 6):s61–5.
   PubMedGoogle Scholar
• Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non–small- cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–1096.
   PubMed Web of Science ®Google Scholar
• Han Y. Current status of proton therapy techniques for lung cancer. Radiat Oncol J. 2019;37:232–248.
   PubMed Web of Science ®Google Scholar
• Shirey RJ, Wu HT. Quantifying the effect of air gap, depth, and range shifter thickness on TPS dosimetric accuracy in superficial PBS proton therapy. J Appl Clin Med Phys. 2018;19:164–173.
   PubMed Web of Science ®Google Scholar
• St. James S, Grassberger C, Lu H-M. Considerations when treating lung cancer with passive scatter or active scanning proton therapy. Transl Lung Cancer Res. 2018;7:210–215.
   PubMed Web of Science ®Google Scholar
• Elsässer T, Weyrather WK, Friedrich T, et al. Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. Int J Radiat Oncol Biol Phys. 2010;78:1177–1183.
   PubMed Web of Science ®Google Scholar
• Matney J, Park PC, Bluett J, et al. Effects of respiratory motion on passively scattered proton therapy versus IMRT for stage III lung cancer: are proton plans more sensitive to breathing motion? Int J Radiat Oncol Biol Phys. 2013;87:576–582.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li Y, Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity- modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010;77:357–366.
   PubMed Web of Science ®Google Scholar
• Brooks ED, Ning MS, Verma V, et al. Proton therapy fro non-samm cell lung cancer: the road ahead. Transl Lung Cancer Res. 2019;8(Suppl 2):S202–S212.
   PubMedGoogle Scholar
• Georg D, Hillbrand M, Stock M, et al. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol. 2008;88(3):368–375.
   PubMed Web of Science ®Google Scholar
• Kadoya N, Obata Y, Kato T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non- small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79:1225–1231.
   PubMed Web of Science ®Google Scholar
• Wink KCJ, Roelofs E, Simone CB, et al. Photons, protons or carbon ions for stage I non-small cell lung cancer - results of the multicentric ROCOCO in silico study. Radiother Oncol. 2018;128:139–146.
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang W, Komaki R, et al. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017;122:274–280.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Iwata H, Ogino H, et al. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer. Radiat Oncol. 2018;13(1):199.
   PubMedGoogle Scholar
• Nantavithya C, Gomez DR, Wei X, et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, dedically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;101:558–563.
   PubMedGoogle Scholar
• Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 2010;28:2475–2480.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26:2457–2463.
   PubMed Web of Science ®Google Scholar
• Harada H, Fuji H, Ono A, et al. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cance. Cancer Sci. 2016;107:1018–1021.
   PubMed Web of Science ®Google Scholar
• Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage iii non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol. 2017;3:e172032.
   PubMed Web of Science ®Google Scholar
• Yang P, Xu T, Gomez DR, et al. Patterns of LRF after IMRT or PSPT passive scattering proton therapy with concurrent chemotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2019;103:123–131.
   PubMed Web of Science ®Google Scholar
• Elhammali A, Blanchard P, Yoder A, et al. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019;136:136–142.
   PubMed Web of Science ®Google Scholar
• Higgins KA, O’Connell K, Liu Y, et al. National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97:128–137.
   PubMed Web of Science ®Google Scholar
• Badiyan SN, Rutenberg MS, Hoppe BS, et al. Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy on the proton collaborative group and university of florida proton therapy institute prospective registry studies. Pract Radiat Oncol. 2019;9:280–288.
   PubMed Web of Science ®Google Scholar
• Kanai T, Furusawa Y, Fukutsu K, et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res. 1997;147(1):78–85.
   PubMed Web of Science ®Google Scholar
• Miyamotoa T, Yamamotoa N, Nishimura H. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003;66(2):127–140.
   PubMedGoogle Scholar
• Miyamoto T, Baba M, Sugane T. Carbon ion radiotherapy for stage i non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007;2(10):916–926.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Baba M, Yamamoto N. Curative treatment of stage i non–small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys. 2007;67(3):750–758.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Miyamoto T, Nakajima M. A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage i non–small cell lung cancer. J Thorac Oncol. 2017;12(4):673–680.
   PubMed Web of Science ®Google Scholar
• Demizu Y, Fujii O, Iwata H, et al. Carbon ion therapy for early-stage non-small-cell lung cancer. Biomed Res Int. 2014;2014:727962.
   PubMedGoogle Scholar
• Takahashi W, Nakajima M, Yamamoto N, et al. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer. 2015;121(8):1321–1327.
   PubMed Web of Science ®Google Scholar
• Saitoh JI, Shirai K, Abe T, et al. A phase I study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer. Anticancer Res. 2018;38:885–891.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yamamoto N, Nakajima M, et al. Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer. Cancer Sci. 2019;110:734–741.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamamoto N, Hayashi K, et al. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis. Radiat Oncol. 2017;12(1):144.
   PubMedGoogle Scholar
• Malouff TD, Mahajan A, Krishnan S. Carbon ion therapy: a modern review of an emerging technology. Front Oncol. 2020;10:82.
   PubMed Web of Science ®Google Scholar
• Pompos A, DuranteM CH. Heavy ions in cancer therapy. JAMA Oncol. 2016;2:1539–1540.
   PubMed Web of Science ®Google Scholar
• Fossati P, Matsufuji N, Kamada T, et al. Radiobiological issues in prospective carbon ion therapy trials. Med Phys. 2018;45(11):e1096– 110.
   PubMed Web of Science ®Google Scholar
• Wild JM, Marshall H, Bock M, et al. MRI of the lung (1/3): methods. Insights Imaging. 2012;3:345–353.
   PubMedGoogle Scholar
• Corradini S, Alongi F, Andratschke N, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol. 2019;14(1):92.
   PubMed Web of Science ®Google Scholar
• Henke L, Kashani R, Yang D, et al. Simulated online adaptive magnetic resonance–guided stereotactic body radiation therapy for the treatment of oligometastatic disease of the abdomen and central thorax: characterization of potential advantages. Int J Radiat Oncol Biol Phys. 2016;96(5):1078–1086.
   PubMed Web of Science ®Google Scholar
• Shirato H, Seppenwoolde Y, Kitamura K, et al. Intrafractional tumor motion: lung and liver. Semin Radiat Oncol. 2004;14(1):10–18.
   PubMed Web of Science ®Google Scholar
• McWilliam A, Faivre-Finn C, Kennedy J, et al. Data mining identifies the base of the heart as a dose-sensitive region affecting survival in lung cancer patients. Int J Radiat Oncol Biol Phys. 2016;96(2):S48–S49.
   Web of Science ®Google Scholar
• Bainbridge H, Salem A, Tijssen RHN, et al. Magnetic resonance imaging in precision radiation therapy for lung cancer. Transl Lung Cancer Res. 2017;6:689–707.
   PubMed Web of Science ®Google Scholar
• Senthi S, Haasbeek CJA, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review. Radiother Oncol. 2013;106:276–282.
   PubMed Web of Science ®Google Scholar
• Oh D, Ahn YC, Seo JM, et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol. 2012;51:596–602.
   PubMed Web of Science ®Google Scholar
• Saenz DL, Paliwal BR, Bayouth JE. A dose homogeneity and conformity evaluation between ViewRay and pinnacle-based linear accelerator IMRT treatment plans. J Med Phys. 2014;39:64–70.
   PubMedGoogle Scholar
• Kishan AU, Cao M, Wang PC, et al. Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: a comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy. Pract Radiat Oncol. 2015;5:330–337.
   PubMed Web of Science ®Google Scholar
• Wooten HO, Green O, Yang M, et al. Quality of intensity modulated radiation therapy treatment plans using a 60Co magnetic resonance image guidance radiation therapy system. Int J Radiat Oncol Biol Phys. 2015;92:771–778.
   PubMed Web of Science ®Google Scholar
• Merna C, Rwigema JC, Cao M, et al. A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer. Med Dosim. 2016;41:87–91.
   PubMed Web of Science ®Google Scholar
• Park JM, Wu HG, Kim HJ, et al. Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR. Radiat Oncol. 2019;14:105.
   PubMed Web of Science ®Google Scholar
• Padgett KR, Simpson GN, Llorente R. Feasibility of adaptive mr-guided stereotactic body radiotherapy (SBRT) of lung tumors. Cureus. 2018;10(4):e2423.
   PubMed Web of Science ®Google Scholar
• Lim G, Bezjak A, Higgins J, et al. Tumor regression and positional changes in non-small cell lung cancer during radical radiotherapy. J Thorac Oncol. 2011;6:531–536.
   PubMed Web of Science ®Google Scholar
• Møller DS, Holt MI, Alber M, et al. Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose. Radiother Oncol. 2016;121:32–38.
   PubMed Web of Science ®Google Scholar
• Matuszak MM, Xiao Y, Presley J, et al. The importance of dry run credentialing for RTOG 1106/ACRIN 6697: a trial of individualized adaptive radiation therapy for patients with locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2012;84:S26–S27.
   Web of Science ®Google Scholar
• Raaijmakers AJ, Raaymakers BW, Lagendijk JJ. Integrating a MRI scanner with a 6 MV radiotherapy accelerator: dose increase at tissue-air interfaces in a lateral magnetic field due to returning electrons. Phys Med Biol. 2005;50:1363–1376.
   PubMed Web of Science ®Google Scholar
• Bainbridge HE, Menten MJ, Fast MF, et al. Treating locally advanced lung cancer with a 1.5 T MR-Linac – effects of the magnetic field and irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapyT MR-Linac. Radiother Oncol. 2017;125(2):280–285.
   PubMed Web of Science ®Google Scholar
• Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced nonsmall cell lung carcinoma treated with chemoradiation: an analysis of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 2012;82:425–434.
   PubMed Web of Science ®Google Scholar
• Al-Shafa F, Arifin AJ, Rodrigues GB, et al. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead? Front Oncol. 2019;9:543.
   PubMed Web of Science ®Google Scholar